BSD Medical Corp., a leading provider of medical systems that utilize heat therapy to treat cancer, announced that the MicroThermX (R) Microwave Ablation System is continuing to receive positive feedback in medical conventions across the world. At the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting held September 10-14 in Munich, Germany, the MicroThermX (R) system was showcased in the CIRSE exhibit space for over 5,000 clinicians from 70 countries in the field of interventional radiology. A BSD ablation engineer revealed that the microwave antennas used in this product can sharply decrease the danger of skin burn as compared to other asynchronous ablations.
The MicroThermX(R) Microwave Ablation System uses an innovative compact design of a microwave generator, single-patient-use disposable antennas and a thermistor-based temperature monitoring system to deliver high power levels of ablation during a single procedure. The MicroThermX(R) utilizes innovative synchronous phased array technology that was developed and patented by BSD. The global market potential for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.
“The CIRSE meeting was effectively used to further develop the Company’s association with international key opinion leaders, many of whom requested demonstrations of the MicroThermX(R),” stated Steven Smith, VP for Marketing and Business Development for BSD in a press release on Thursday. “The increasing clinical interest in the MicroThermX(R) was evident by a constant stream of interested clinicians and medical distributors from around the world.”
Microwave ablation is the most recent development in the field of tumor ablation and allows for a flexible approach to tumor treatment that uses imaging guidance to localize the tumor for placement of a thin microwave antenna directly into the tumor. The microwave generator emits an electromagnetic wave that agitates water molecules in the surrounding tissue, producing friction and heat, thus killing the cells. The main advantages of the microwave technology include larger tumor ablation volumes, faster ablation times and an improved convection profile. Microwave ablation has promising potential in the treatment of primary and secondary liver disease, primary and secondary lung malignancies, renal and adrenal tumors, and bone metastases.
For more information on BSD Medical, please visit www.BSDMedical.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
